Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.53 |
| ▸ | KDR | P35968 | 8/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.45 |
| ▸ | MET | P08581 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25029462 | 0.91 | AXL (0.51) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL25028726 | 0.91 | KDR (0.55) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL25028724 | 0.84 | KDR (0.54) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL1132666 | 0.82 | AXL (0.61) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL25028729 | 0.82 | KDR (0.52) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL25028717 | 0.82 | PDGFRB (0.54) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL30066135 | 0.81 | AXL (0.55) | AXLKDRPDGFRAMETMERTK | |
| SCHEMBL1132352 | 0.81 | AXL (0.55) | AXLKDRPDGFRAMETMERTK | |
| SCHEMBL25028722 | 0.81 | KDR (0.53) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL25029459 | 0.81 | KDR (0.51) | AXLKDRPDGFRAMETAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912663-B2 | Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses | SHANGHAI AB PHARMATECH LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11912663-B2 | Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses | SHANGHAI AB PHARMATECH LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-20230124784-A1 | MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES | SHANGHAI AB PHARMATECH LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912663-B2 | Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses | ABL1, ERBB2, RET | AXL 134/4885KDR 429/4885PDGFRA 442/4885 |
| US-20230124784-A1 | MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES | ABL1, ERBB2, RET | AXL 134/4885KDR 429/4885PDGFRA 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.